CGEN:NSD-Compugen Ltd (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 7.80

Change

+0.20 (+2.63)%

Market Cap

USD 0.64B

Volume

1.15M

Average Target Price

USD 17.00 (+117.95%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+4.63 (+2.34%)

USD79.44B 132.60 106.34
REGN Regeneron Pharmaceuticals, Inc

+12.43 (+2.37%)

USD55.78B 14.90 11.77
BNTX BioNTech SE

+10.35 (+5.08%)

USD49.23B -99,999.99 35.63
VRTX Vertex Pharmaceuticals Incorpo..

+0.87 (+0.46%)

USD48.53B 17.87 12.86
ALXN Alexion Pharmaceuticals, Inc

-0.58 (-0.32%)

USD39.90B 58.60 42.42
BGNE BeiGene, Ltd

-4.17 (-1.25%)

USD31.22B N/A N/A
GMAB Genmab A/S

-1.04 (-2.33%)

USD29.17B 26.59 3.71
SGEN Seagen Inc

+2.06 (+1.36%)

USD27.46B 42.22 39.29
RPRX Royalty Pharma plc

+0.52 (+1.19%)

USD26.73B 22.60 15.75
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CGEN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -35.59% 11% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.59% 11% F 6% F
Trailing 12 Months  
Capital Gain -49.42% 11% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -49.42% 11% F 4% F
Trailing 5 Years  
Capital Gain 20.56% 52% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.56% 52% F 32% F
Average Annual (5 Year Horizon)  
Capital Gain 56.23% 79% C+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 56.23% 79% C+ 87% B+
Risk Return Profile  
Volatility (Standard Deviation) 120.09% 21% F 12% F
Risk Adjusted Return 46.82% 72% C- 66% D
Market Capitalization 0.64B 61% D- 55% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 5.74 33% F 27% F
Price / Cash Flow Ratio -22.72 80% B- 84% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -28.87% 77% C+ 31% F
Return on Invested Capital -39.84% 61% D- 20% F
Return on Assets -16.45% 71% C- 21% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 6.73 38% F 22% F
Short Percent 9.00% 38% F 22% F
Beta 2.32 11% F 8% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector